Brought to you by 
Merck puts up $80mm to buy Abmaxis
May 2006
Executive Summary
Merck has agreed to pay $80mm in cash to acquire human monoclonal antibody therapeutics developer Abmaxis, which will now operate as a wholly owned subsidiary.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Acquisition of Private Biotech
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck puts up $80mm to buy Abmaxis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice